Stockholders Equity (Tables)
|
6 Months Ended |
Jun. 30, 2025 |
|---|
| Stockholders Equity [Abstract] |
|
| Schedule of Outstanding Warrants to Purchase Common Stock Issued to Stockholders |
As of June 30, 2025, the Company had the
following outstanding warrants to purchase Common Stock issued to stockholders:
| Warrant |
| Issuance Date |
| Expiration
Date |
| Exercise
Price
Per Share |
|
| Number of
Shares of
Common Stock
Underlying
Warrants |
|
| 2021 Registered Direct Offering Warrants |
| SPA (July 28, 2021) |
| January 28, 2027 |
| |
50.00 |
|
| |
281,251 |
|
| Merger Warrants |
| March 15, 2024 |
| January 28, 2027 |
| |
50.00 |
|
| |
216,650 |
|
| Private Placement Warrants |
| March 15, 2024 |
| July 9, 2026 |
| |
2.31 |
|
| |
3,865,322 |
|
| Registered Pre-Funded Warrants |
| February 25, 2025 |
| April 21, 2030 |
| |
0.0001 |
|
| |
805,231 |
|
| Private Pre-Funded Warrants |
| February 25, 2025 |
| April 21, 2030 |
| |
0.0001 |
|
| |
1,105,323 |
|
| Common Warrants |
| February 25, 2025 |
| April 21, 2030 |
| |
0.9306 |
|
| |
5,937,466 |
|
| Inducement Warrants |
| February 25, 2025 |
| April 21, 2030 |
| |
0.9306 |
|
| |
6,955,528 |
|
| A&R Warrants |
| February 25, 2025 |
| April 21, 2030 |
| |
0.0001 |
|
| |
2,994,419 |
|
| |
| |
| |
| |
|
|
| |
22,161,190 |
|
|
| Schedule of Stock Option Plans |
A summary of options granted to purchase
the Company’s Common Stock under the Company’s share option plans is as follows:
| |
| For the Six Months Ended
June 30, 2025 |
|
| |
| Number of
Options |
|
| Weighted
Average
Exercise
Price |
|
| Aggregate
Intrinsic
Value |
|
| Outstanding at the beginning of period |
| |
2,002,365 |
|
| |
4.09 |
|
| |
15 |
|
| Granted |
| |
1,210,116 |
|
| |
0.54 |
|
| |
|
|
| Forfeited |
| |
(170,460 |
) |
| |
3.63 |
|
| |
|
|
| Expired |
| |
(38,662 |
) |
| |
2.83 |
|
| |
|
|
| Exercised |
| |
- |
|
| |
- |
|
| |
|
|
| Outstanding at the end of period |
| |
3,003,359 |
|
| |
2.70 |
|
| |
9 |
|
| Exercisable at the end of period |
| |
363,382 |
|
| |
6.08 |
|
| |
|
|
| Weighted average remaining contractual life of outstanding options – years as of June 30, 2025 |
| |
8.79 |
|
| |
|
|
| |
|
|
|
| Schedule of Outstanding Compensation Related Warrants to Purchase Common Stock |
As of June 30, 2025, the Company had the
following outstanding compensation related warrants to purchase Common Stock:
| Warrant |
| Issuance
Date |
| Expiration
Date |
| Exercise
Price
Per Share |
|
| Number of
Shares of
Common Stock
Underlying
Warrants |
|
| Private Warrants issued to scientific founders |
| November 27, 2017 |
| - |
| |
- |
|
| |
298 |
|
| Landlord Warrants |
| March 15, 2024 |
| January 28, 2027 |
| |
50.00 |
|
| |
25,000 |
|
| Agents Warrants |
| March 15, 2024 |
| July 9, 2026 |
| |
2.31 |
|
| |
952,381 |
|
| |
| |
| |
| |
|
|
| |
977,679 |
|
|
| Schedule of Stock-Based Payment Expenses |
The following table sets forth the total
stock-based payment expenses resulting from options granted, included in the statements of operations:
| |
|
Three Months Ended
June 30, |
|
|
Six Months Ended
June 30, |
|
| |
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
| Research and development expenses, net |
|
|
279 |
|
|
|
(2 |
) |
|
|
467 |
|
|
|
63 |
|
| General and administrative |
|
|
417 |
|
|
|
79 |
|
|
|
888 |
|
|
|
191 |
|
| |
|
|
696 |
|
|
|
77 |
|
|
|
1,355 |
|
|
|
254 |
|
|